articleTop 10% cited

Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate

Clinical Cancer Research · 2004 · Vol. 10(20) · pp. 7063–7070

Kevin J. Hamblett✉(Seagen (United States))Peter D. Senter(Seagen (United States))Dana F. Chace(Seagen (United States))Michael Sun(Seagen (United States))Joel S. Lenox(Seagen (United States))Charles G. Cerveny(Seagen (United States))Kim M. Kissler(Seagen (United States))Starr X. Bernhardt(Seagen (United States))Anastasia K. Kopcha(Seagen (United States))Roger F. Zabinski(Seagen (United States))Damon L. Meyer(Seagen (United States))Joseph A. Francisco(Seagen (United States))

View via DOI Publisher page

Abstract

By decreasing drug loading per antibody, the therapeutic index was increased demonstrating that drug loading is a key design parameter for antibody-drug conjugates.

Monoclonal and Polyclonal Antibodies Research HER2/EGFR in Cancer Research Cell Adhesion Molecules ResearchConjugateIn vivoMonoclonal antibodyAntibodyPharmacologyDrugPharmacokineticsPotencyIn vitroChemistry

MeSH terms

AnimalsAntibodies, MonoclonalHumansOligopeptidesTransplantation, HeterologousTumor Cells, CulturedLymphoma, Large B-Cell, DiffuseKi-1 AntigenImmunoconjugatesMaximum Tolerated DoseMice

Citations

1,196

FWCI

6.52

field-weighted impact

References

Percentile

97%

vs. same field & year

Citations per year

Cited by

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*